276862-85-2

Usage

Uses

Used in Pharmaceutical Industry:
1H-Pyrrolo[3,2-b]pyridine-3-carboxaldehyde (9CI) is used as a key intermediate in the synthesis of pharmaceuticals for its potential pharmacological properties. It contributes to the development of new drugs by serving as a structural component that can be further modified or combined with other molecules to create therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, 1H-Pyrrolo[3,2-b]pyridine-3-carboxaldehyde (9CI) is employed as a versatile building block. Its unique structure allows for various chemical reactions, enabling the creation of a wide range of organic compounds with different functionalities and applications.
Used in Medicinal Chemistry:
1H-Pyrrolo[3,2-b]pyridine-3-carboxaldehyde (9CI) is utilized in medicinal chemistry for its potential role in the development of new therapeutic agents. Its structural features make it a promising candidate for the design and synthesis of novel compounds with potential medicinal applications, including the treatment of various diseases and conditions.

InChI:InChI=1/C8H6N2O/c11-5-6-4-10-7-2-1-3-9-8(6)7/h1-5,10H

Upstream product

• 272-49-1 1H-pyrrolo[3,2-b]pyridine 
• 100-97-0 hexamethylenetetramine 

Downstream Products

• 1428969-55-4 2-((3-methoxyphenyl)amino)-2-phenyl-1-(1H-pyrrolo[3,2-b]pyridin-3-yl)ethanone 
• 1196151-62-8 1H-pyrrolo[3,2-b]pyridine-3-carbonitrile 

Relevant academic research and scientific papers

Amide derivatives of 4-azaindole: Design, synthesis, and EGFR targeting anticancer agents

A series of amide derivatives of azaindole-oxazoles (11a–n) were designed and synthesized and their structures were confirmed by 1HNMR, 13CNMR and mass spectral analysis. Further, these derivatives were screened for their anticancer activity against human cancer cell lines viz; MCF7 (breast), A549 (lung) and A375 (melanoma). In vitro anticancer activity screening indicated that most of the hybrids exhibited potent inhibitory activities in a variety of cancer cell lines. Among the compounds 11d, 11e, 11f, 11j, 11k, 11l, 11m, and 11n were exhibited more potent activity than standard, in those mainly two compounds 11m and 11j were exhibited excellent activity in MCF-7 cell line with IC50 values 0.034 and 0.036 μM. Moreover, all these compounds were carried out their molecular docking studies on EGFR receptor results indicated that two potent compounds 11m and 11j were strongly binds to protein EGFR (PDB ID: 4hjo). It was found that the energy calculations were in good agreement with the observed IC50 values.

Tryptophan-based fluorophores for studying protein conformational changes

With the continuing interest in deciphering the interplay between protein function and conformational changes, small fluorescence probes will be especially useful for tracking changes in the crowded protein interior space. Presently, we describe the poten

VIRAL REPLICATION INHIBITORS

The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

3-Amino-1-arylpropyl azaindoles and uses thereof

The present invention provides compounds of the formula: or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein p, Ar, R1, R2, R3, Ra, Rb, Rc, Rd and Re are defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.

THERAPEUTIC AGENTS I

Compounds of formula(I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders, and pharmaceutical compositions containing them.